Another 'weight' for Contrave; Orexigen falls on FDA delay
Already trailing approvals of obesity drugs Belviq (lorcaserin) and Qsymia (phentermine/topiramate) by two years, Orexigen Therapeutics Inc.'s Contrave (naltrexone/bupropion) is facing another delay at the hands of the FDA, which pushed back the PDUFA date by three months to Sept. 11.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter